{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T11:42:20Z","timestamp":1778326940168,"version":"3.51.4"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["JPJSCCA20170007"],"award-info":[{"award-number":["JPJSCCA20170007"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19ae0101026"],"award-info":[{"award-number":["JP19ae0101026"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Introduction<\/jats:title>\n<jats:p>Molecular and cellular characteristics of the relapse-prone subset within triple-negative breast cancer (TNBC) remain unclear. Aberrant glycosylation is involved in the malignant behavior of cancer cells. In the present study, we aimed to reveal glycan profiles unique to relapsed TNBC patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Thirty TNBC patients who did not undergo neoadjuvant chemotherapy but postoperative standard adjuvant therapy from 2009 through 2016 at Juntendo Hospital were investigated. TNBC cells were resected from primary breast cancer sections of formalin-fixed surgical specimens using laser-assisted microdissection. The binding intensities of the extracted glycoproteins to 45 lectins were quantified using lectin microarray and compared between relapsed and non-relapsed patients. Immunohistochemical staining with TJA-II lectin in specimen sections was performed.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Five patients relapsed during the follow-up (range 37\u2013123 months). Lectin microarray analysis revealed that 7 out of 45 lectins showed significant differences in binding intensity between the relapsed and the non-relapsed group. TJA-II, ACA, WFA, and BPL showed stronger binding in the relapsed group. PNGase F treatment of TNBC cell lysates suggested that TJA-II and ACA bind <jats:italic>O<\/jats:italic>-glycans. TJA-II staining of tissue sections revealed strong binding to cell surface membranes and to the cytoplasm of TNBC cells, but not to other types of cells. Significantly more TNBC cells were stained in tissue sections from relapsed than non-relapsed patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>TNBC cells from relapsed patients showed a unique lectin reactivity, with higher levels of TJA-II (also WFA and BPL) binding than in non-relapsed patients. The results are potentially useful to develop new prognostic and therapeutic tools.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0250747","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T17:44:51Z","timestamp":1620755091000},"page":"e0250747","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Glycans unique to the relapse-prone subset within triple-negative breast cancer as revealed by lectin array-based analysis of surgical specimens"],"prefix":"10.1371","volume":"16","author":[{"given":"Madoka","family":"Sakata-Matsuzawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaori","family":"Denda-Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhiko","family":"Fujihira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki","family":"Noji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin Beate","family":"Ishii-Schrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misato","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuya","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8935-0768","authenticated-orcid":true,"given":"Yoshiya","family":"Horimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsue","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4709-3131","authenticated-orcid":true,"given":"Tatsuro","family":"Irimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,5,11]]},"reference":[{"issue":"20","key":"pone.0250747.ref001","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"WD Foulkes","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"pone.0250747.ref002","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","article-title":"Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011","volume":"22","author":"A Goldhirsch","year":"2011","journal-title":"Annals of Oncology"},{"issue":"15 Pt 1","key":"pone.0250747.ref003","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"R Dent","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"36","key":"pone.0250747.ref004","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.1200\/JCO.2006.06.5664","article-title":"Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer","volume":"24","author":"BG Haffty","year":"2006","journal-title":"J Clin Oncol"},{"issue":"7","key":"pone.0250747.ref005","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"BD Lehmann","year":"2011","journal-title":"The Journal of Clinical Investigation"},{"issue":"10","key":"pone.0250747.ref006","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.ajpath.2017.05.018","article-title":"Triple-Negative Breast Cancer: Next-Generation Sequencing for Target Identification","volume":"187","author":"JD Marotti","year":"2017","journal-title":"Am J Pathol"},{"issue":"8","key":"pone.0250747.ref007","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","volume":"379","author":"JK Litton","year":"2018","journal-title":"N Engl J Med"},{"issue":"22","key":"pone.0250747.ref008","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","volume":"379","author":"P Schmid","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0250747.ref009","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.cell.2006.08.019","article-title":"Glycosylation in cellular mechanisms of health and disease","volume":"126","author":"K Ohtsubo","year":"2006","journal-title":"Cell"},{"issue":"6202","key":"pone.0250747.ref010","doi-asserted-by":"crossref","first-page":"1254009","DOI":"10.1126\/science.1254009","article-title":"Innate lymphoid cells regulate intestinal epithelial cell glycosylation","volume":"345","author":"Y Goto","year":"2014","journal-title":"Science"},{"issue":"23","key":"pone.0250747.ref011","first-page":"5309","article-title":"Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism","volume":"56","author":"S Hakomori","year":"1996","journal-title":"Cancer Res"},{"issue":"1","key":"pone.0250747.ref012","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1158\/0008-5472.CAN-17-1636","article-title":"MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer","volume":"78","author":"T Maeda","year":"2018","journal-title":"Cancer Res"},{"issue":"5","key":"pone.0250747.ref013","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.celrep.2017.07.027","article-title":"Blockage of Core Fucosylation Reduces Cell-Surface Expression of PD-1 and Promotes Anti-tumor Immune Responses of T Cells","volume":"20","author":"M Okada","year":"2017","journal-title":"Cell Rep"},{"issue":"23","key":"pone.0250747.ref014","doi-asserted-by":"crossref","first-page":"13811","DOI":"10.1074\/jbc.271.23.13811","article-title":"Aberrant glycosylation of E-cadherin enhances cell-cell binding to suppress metastasis","volume":"271","author":"M Yoshimura","year":"1996","journal-title":"J Biol Chem"},{"issue":"8","key":"pone.0250747.ref015","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.bcp.2009.12.002","article-title":"Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin","volume":"79","author":"GL Beretta","year":"2010","journal-title":"Biochemical Pharmacology"},{"key":"pone.0250747.ref016","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.biopha.2015.07.001","article-title":"Inhibition of protein glycosylation reverses the MDR phenotype of cancer cell lines","volume":"74","author":"K Wojtowicz","year":"2015","journal-title":"Biomed Pharmacother"},{"key":"pone.0250747.ref017","doi-asserted-by":"crossref","first-page":"13796","DOI":"10.1038\/ncomms13796","article-title":"GALNT14 promotes lung-specific breast cancer metastasis by modulating self-renewal and interaction with the lung microenvironment","volume":"7","author":"K-H Song","year":"2016","journal-title":"Nat Commun"},{"issue":"1","key":"pone.0250747.ref018","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13058-015-0544-9","article-title":"Lectin RCA-I specifically binds to metastasis-associated cell surface glycans in triple-negative breast cancer","volume":"17","author":"S-M Zhou","year":"2015","journal-title":"Breast Cancer Res"},{"issue":"31","key":"pone.0250747.ref019","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"AC Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"pone.0250747.ref020","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0076-6879(10)78007-1","article-title":"Differential glycan profiling by lectin microarray targeting tissue specimens","volume":"478","author":"A Kuno","year":"2010","journal-title":"Methods Enzymol"},{"issue":"9","key":"pone.0250747.ref021","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/labinvest.2017.53","article-title":"Assessment of tumor characteristics based on glycoform analysis of membrane-tethered MUC1","volume":"97","author":"A Matsuda","year":"2017","journal-title":"Lab Invest"},{"key":"pone.0250747.ref022","doi-asserted-by":"crossref","first-page":"43560","DOI":"10.1038\/srep43560","article-title":"A standardized method for lectin microarray-based tissue glycome mapping","volume":"7","author":"X Zou","year":"2017","journal-title":"Sci Rep"},{"issue":"5","key":"pone.0250747.ref023","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.1999.17.5.1474","article-title":"Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer","volume":"17","author":"JM Harvey","year":"1999","journal-title":"J Clin Oncol"},{"issue":"35","key":"pone.0250747.ref024","doi-asserted-by":"crossref","first-page":"25414","DOI":"10.1016\/S0021-9258(19)74057-5","article-title":"Purification and characterization of a Fuc alpha 1\u2014>2Gal beta 1\u2014> and GalNAc beta 1\u2014>-specific lectin in root tubers of Trichosanthes japonica","volume":"267","author":"K Yamashita","year":"1992","journal-title":"J Biol Chem"},{"issue":"2","key":"pone.0250747.ref025","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3892\/ijo.2013.2187","article-title":"Involvement of B3GALNT2 overexpression in the cell growth of breast cancer","volume":"44","author":"T Matsuo","year":"2014","journal-title":"Int J Oncol"},{"key":"pone.0250747.ref026","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cca.2019.05.015","article-title":"Advances in the relationship between glycosyltransferases and multidrug resistance in cancer","volume":"495","author":"Y Wu","year":"2019","journal-title":"Clin Chim Acta"},{"issue":"172","key":"pone.0250747.ref027","doi-asserted-by":"crossref","first-page":"SE137","DOI":"10.4052\/tigg.1728.1SE","article-title":"Carbohydrate-Binding Specificity of Human Galectins: An Overview by Frontal Affinity Chromatography","volume":"30","author":"J Iwaki","year":"2018","journal-title":"Trends in Glycoscience and Glycotechnology"},{"key":"pone.0250747.ref028","article-title":"Impact of Galectins in Resistance to Anticancer Therapies","author":"P Navarro","year":"2020","journal-title":"Clin Cancer Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0250747","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T17:45:19Z","timestamp":1620755119000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0250747"}},"subtitle":[],"editor":[{"given":"Lu-Gang","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,5,11]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0250747","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,11]]}}}